deltatrials
Completed PHASE4 NCT00649610

Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain

Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily vs. Diclofenac 75 mg Twice Daily in Subjects With Acute Low Back Pain

Sponsor: Pfizer

Conditions Low Back Pain
Interventions diclofenac valdecoxib
Updated 7 times since 2017 Last updated: Apr 7, 2008 Started: Nov 30, 2002 Completion: May 31, 2003

Listed as NCT00649610, this PHASE4 trial focuses on Low Back Pain and remains completed. Sponsored by Pfizer, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bogota D.C, Colombia, Bogotá, Colombia, Bs. As., Argentina, Buenos Aires, Argentina, Cali-valle, Colombia, Caracas, Venezuela, Cartago, Costa Rica, Curitiba, Brazil, Goiânia, Brazil, Hatillo Centro, Costa Rica and 8 more location s